CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 67 filers reported holding CONCERT PHARMACEUTICALS INC in Q2 2015. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $5,856,253 | -8.3% | 1,002,783 | +5.2% | 1.26% | +41.9% |
Q3 2022 | $6,384,000 | +123.2% | 952,783 | +40.2% | 0.89% | +189.5% |
Q2 2022 | $2,860,000 | -41.1% | 679,400 | +76.9% | 0.31% | -29.0% |
Q4 2020 | $4,854,000 | +59.5% | 384,039 | +23.9% | 0.43% | +44.1% |
Q3 2020 | $3,044,000 | -56.3% | 310,000 | -55.8% | 0.30% | -54.4% |
Q2 2020 | $6,972,000 | -22.1% | 700,710 | -30.8% | 0.66% | -41.4% |
Q1 2020 | $8,955,000 | +593.1% | 1,013,039 | +623.6% | 1.12% | +956.6% |
Q4 2019 | $1,292,000 | +57.0% | 140,000 | 0.0% | 0.11% | -16.5% |
Q3 2019 | $823,000 | -75.9% | 140,000 | -22.2% | 0.13% | -74.6% |
Q4 2015 | $3,415,000 | -9.0% | 180,000 | -10.0% | 0.50% | +4.4% |
Q3 2015 | $3,754,000 | +1490.7% | 200,000 | +1161.2% | 0.48% | +1982.6% |
Q2 2015 | $236,000 | -95.8% | 15,858 | -95.8% | 0.02% | -96.1% |
Q1 2015 | $5,679,000 | +184.2% | 375,000 | +150.0% | 0.59% | +73.8% |
Q4 2014 | $1,998,000 | +598.6% | 150,000 | +560.8% | 0.34% | +871.4% |
Q3 2014 | $286,000 | – | 22,700 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
L1 Capital Pty Ltd | 1,050,124 | $10,312,000 | 3.31% |
Alambic Investment Management, L.P. | 19,934 | $196,000 | 2.15% |
INGALLS & SNYDER LLC | 1,363,603 | $13,391,000 | 0.92% |
ACUTA CAPITAL PARTNERS, LLC | 300,000 | $2,946,000 | 0.80% |
RA Capital Management | 1,858,474 | $18,250,000 | 0.33% |
Perceptive Advisors | 2,150,641 | $21,119,000 | 0.31% |
SPHERA FUNDS MANAGEMENT LTD. | 310,000 | $3,044,000 | 0.30% |
Eversept Partners, LP | 103,829 | $1,019,601 | 0.23% |
Opaleye Management Inc. | 100,000 | $982,000 | 0.19% |
GSA CAPITAL PARTNERS LLP | 58,095 | $570,000 | 0.10% |